Lev Verkh
About Lev Verkh
Lev Verkh is the Chief Regulatory and Clinical Development Officer known for co-authoring a publication on the use of mesenchymal stem cells in treating chronic stroke.
Lev Verkh - Chief Regulatory and Clinical Development Officer
Lev Verkh holds the position of Chief Regulatory and Clinical Development Officer. In this role, he oversees regulatory strategies and clinical development initiatives aimed at advancing medical research and therapies. His expertise ensures that new treatments comply with regulatory standards and successfully navigate through clinical trials. Verkh's work is integral to the process of bringing innovative medical products to the market, ensuring both safety and efficacy.
Lev Verkh - Scientific Publications
Lev Verkh has contributed to the scientific community through his co-authorship of the publication 'Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke.' This study investigates the safety and preliminary efficacy of using intravenous allogeneic mesenchymal stem cells as a treatment for chronic stroke. Verkh's research aims to uncover potential new therapies that can provide better outcomes for patients suffering from chronic stroke.